Anitocabtagene autoleucel

阿尼基奥仑赛

Report date: 2026/05/06 20:02:28

Base Information

Drug NameAnitocabtagene autoleucel
Drug Alias NameiMMagine-1anito-celCART-ddBCMAKite-772
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsAutoimmune DiseasesNeuromuscular ManifestationsAutoimmune Diseases of the Nervous System +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[15] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesArcellx Inc
China Registration ClassN/A

Develop Information

Active CompaniesKite PharmaKite Pharma IncArcellx Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesNeuromuscular ManifestationsAutoimmune Diseases of the Nervous System +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A